Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2933-2940

  Zhong, Jieying ^a   Chau, Ying ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL STRUCTURE; CIRCULAR DICHROISM; CYCLIZATION; CYTOTOXICITY; ERYTHROCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; CELL SHAPE; DRUG SCREENING ASSAYS, ANTITUMOR; HEMOLYSIS; HUMANS; MATRIX METALLOPROTEINASE 14; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, SECONDARY; RABBITS; SODIUM DODECYL SULFATE; WATER;

EID: 54049085426     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0528     Document Type: Article

References (44)

1. Ganz T, Selsted ME, Szklarek D, et al. Defensins - natural peptide antibiotics of human-neutrophils. J Clin Investig 1985;76:1427-35.
2. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin - isolation, characterization of 2 active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A 1987;84:5449-53.
3. Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML, Hodges RS. Rational design of a-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J Biol Chem 2005;280:12 316-29.
4. Shai Y. From innate immunity to de-novo designed antimicrobial peptides. Curr Pharmaceutical Design 2002;8:715-25.
5. Dennison SR, Whittaker M, Harris F, Phoenix DA. Anticancer α-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci 2006;7:487-99.
6. Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005;62:784-90.
7. Leuschner C, Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr Pharmaceut Des 2004;10:2299-310.
8. Jin Y, Hammer J, Pate M, et al. Antimicrobial activities and structures of two linear cationic peptide families with various amphipathic β-sheet and α-helical potentials. Antimicrob Agents Chemother 2005;49:4957-64.
9. Bechinger B. Structure and function of membrane-lytic peptides. Crit Rev Plant Sci 2004;23:271-92.
10. Ladokhin AS, White SH. Folding of amphipathic α-helices on membranes: energetics of helix formation by melittin. J Mol Biol 1999;285:1363-9.
11. Mazzuca C, Stella L, Venanzi M, Formaggio F, Toniolo C, Pispisa B. Mechanism of membrane activity of the antibiotic trichogin GA IV: a two-state transition controlled by peptide concentration. Biophys J 2005;88:3411-21.
12. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002;66:236-48.
13. Garnier-Suillerot A, Marbeuf-Gueye C, Salerno M, et al. Analysis of drug transport kinetics in implications for drug action. Curr Med Chem 2001;8:51-64.
14. Potrich C, Tomazzolli R, Dalla Serra M, et al. Cytotoxic activity of a tumor protease-activated pore-forming toxin. Bioconjug Chem 2005;16:369-76.
15. Warren P, Li LJ, Song W, et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two g-linked glutamate residues at the COOH terminus. Cancer Res 2001;61:6783-7.
16. Holle L, Song W, Holle E, Wei YZ, Wagner T, Yu XZ. A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int J Oncol 2003;22:93-8.
17. Papo N, Shai Y. New lytic peptides based on the DL-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 2003;42:9346-54.
18. Marks AJ, Cooper MS, Anderson RJ, et al. Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res 2005;65:2373-7.
19. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
20. Vartak DG, Gemeinhart RA. Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target 2007;15:1-20.
21. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
22. Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T, Seiki M. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem 2006;281:37576-85.
23. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107:789-800.
24. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446-51.
25. Mucha A, Cuniasse P, Kannan R, et al. Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently synthetic substrates containing unusual amino acids in their P1′ positions. J Biol Chem1 998;273:27 63-8.
26. Ohkubo S, Miyadera K, Sugimoto Y, Matsuo K, Wierzba K, Yamada Y. Identification of substrate sequences for membrane type-1 matrix metalloproteinase using bacteriophage peptide display library. Biochem Biophys Res Commun 1999;266:308-13.
27. Kridel SJ, Sawai H, Ratnikov BI, et al. A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem 2002;277:23788-93.
28. Oren Z, Shai Y. Cyclization of a cytolytic amphipathic a-helical peptide and its diastereomer: effect on structure, interaction with model membranes, and biological function. Biochemistry 2000;39:6103-14.
29. Unger T, Oren Z, Shai Y. The effect of cyclization of magainin 2 and melittin analogues on structure, function, and model membrane interactions: implication to their mode of action. Biochemistry 2001;40:6388-97.
30. Lee DL, Powers JPS, Pflegerl K, Vasil ML, Hancock REW, Hodges RS. Effects of single D-amino acid substitutions on disruption of β-sheet structure and hydrophobicity in cyclic 14-residue antimicrobial peptide analogs related to gramicidin S. J Peptide Res 2004;63:69-84.
31. Raby BN, Polette M, Gilles C, et al. Quantitative cell dispersion analysis: new test to measure tumor cell aggressiveness. Int J Cancer 2001;93:644-52.
32. Ratnikov BI, Deryugina EI, Strongin AY. Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest 2002;82:1583-90.
33. Lafleur MA, Mercuri FA, Ruangpanit N, Seiki M, Sato H, Thompson EW. Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain. J Biol Chem 2006;281:6826-40.
34. Job GE, Kennedy RJ, Heitmann B, Miller JS, Walker SM, Kemp DS. Temperature- and length-dependent energetics of formation for polyalanine helices in water: assignment of w(Ala)(n T) and temperature-dependent CD ellipticity standards. J Am Chem Soc 2006;128:8227-33.
35. Steiner V, Bornsen KO, Schar M, et al. Analysis of synthetic peptides using matrix-assisted laser desorption ionization mass-spectrometry. Peptide Res 1992;5:25-9.
36. Schiffer M, Edmundson AB. Use of helical wheels to represent the structures of proteins and to identify segments with helical potential. Biophys J 1967;7:121-35.
37. DeLano WL. The PyMOL molecular graphics system. DeLano Scientific; 2002.
38. Haupt LM, Thompson EW, Trezise AEO, Irving RE, Irving MG, Griffiths LR. In vitro and in vivo MMP gene expression localisation by in situ-RT-PCR in cell culture and paraffin embedded human breast cancer cell line xenografts. Bmc Cancer 2006;6.
39. Boman HG, Hultmark D. Cell-free immunity in insects. Annu Rev Microbiol 1987;41:103-26.
40. Tu ZG, Ha J, Kharldia R, Meng XG, Liang JF. Improved stability and selectivity of lytic peptides through self-assembly. Biochem Biophys Res Commun 2007;361:712-7.
41. Wu YI, Munshi HG, Sen R, et al. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem 2004;279:8278-89.
42. Wieprecht T, Apostolov O, Beyermann M, Seelig J. Thermodynamics of the α-helix-coil transition of amphipathic peptides in a membrane environment: implications for the peptide-membrane binding equilibrium. J Mol Biol 1999;294:785-94.
43. Jacobs RE, White SH. The nature of the hydrophobic binding of small peptides at the bilayer interface: implications for the insertion of transbilayer helices. Biochemistry 1989;28:3421-37.
44. Sharon M, Oren Z, Shai Y, Anglister J. 2D-NMR and ATR-FTIR study of the structure of a cell-selective diastereomer of melittin and its orientation in phospholipids. Biochemistry 1999;38:15305-16.